Kite (Gilead) Deal History & Licensing Activity
Kite (Gilead) is a large pharma headquartered in US. Over the past three years, Kite (Gilead) has been involved in 11 licensing and acquisition transactions, with a primary focus on CAR-T (6 deals). The company currently has 27 active clinical trials, primarily in Hematological Malignancies.
Deals (12mo)
5
Active Trials
27
Top Modality
CAR-T
Focus Area
Hematological Malignancies
Kite (Gilead) Recent Deal Activity
Licensing, acquisition, and partnership transactions involving Kite (Gilead) in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| research pact extension | Gilead | Other | Unknown | collaboration | Jun 27, 2026 |
| Tubulis (company acquisition) | Gilead | ADC | Unknown | acquisition | Jun 15, 2026 |
| Tubulis ADC platform/pipeline | Gilead Sciences | ADC | Unknown | acquisition | Apr 7, 2026 |
| anito-cel | Gilead Sciences | CAR-T | Phase 3 | acquisition | Feb 23, 2026 |
| Undisclosed | Gilead Sciences | CAR-T | Unknown | collaboration | Oct 1, 2025 |
Kite (Gilead) Pipeline Focus
Therapeutic areas and modalities where Kite (Gilead) is most active based on deal history and clinical trial data.
Therapeutic Areas
Modalities
Kite (Gilead) Clinical Pipeline
Kite (Gilead) has 27 active clinical trials across 4 development phases.
3
Unknown
14
Phase 1
6
Phase 2
4
Phase 3
See How Your Asset Matches Kite (Gilead)'s Portfolio
Use Solidus to benchmark upfront payments, milestones, and royalties for Hematological Malignancies assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Oncology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for oncology
CAR-T Benchmarks
Upfront, milestone, and royalty benchmarks for car-t deals
ADC Benchmarks
Upfront, milestone, and royalty benchmarks for adc deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 700+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
Industry-wide analysis of deal terms, trends, and market dynamics
About Kite (Gilead) Licensing & Deal Activity
Kite (Gilead) is a large pharma company based in US that has been actively engaged in licensing transactions across the biopharma landscape. With 11 deals over the past three years, Kite (Gilead) ranks among the most acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Kite (Gilead) include Hematological Malignancies (14 deals and trials), Oncology (7 deals and trials), Mega Deals (4 deals and trials), and Codev Deals (2 deals and trials). In terms of modality, Kite (Gilead) has shown particular interest in car-t, adc, small molecules.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Kite (Gilead) and 700+ other biopharma companies. Use our Solidus to benchmark your asset against Kite (Gilead)'s historical deal terms, or explore all company profiles to find the best partner match for your pipeline.